Skip to main content
Premium Trial:

Request an Annual Quote

NextGen, BD Clontech, PrecisionMed


NextGen Sciences has begun rolling out its fully automated 2-dimensional electrophoresis system, the a2DE, which the company bills as being the only system that can run 2D gel electrophoresis without supervision or intervention. NextGen also launched its expressionfactory technology, which enables researchers to perform systematic, automated, and high throughput protein expression and purification.

The launches coincide with the opening of NextGen’s first international office, NextGen Sciences, in Bedford, Mass.,which the company announced last week. The facility will support the company’s customer base in the United States, and will provide NextGen Sciences with a sales, support, and manufacturing base for their technologies outside the UK.

BD Clontech has launched its RNA/cDNA Quality Assay, which is designed to determine the quality of human RNA and cDNA samples using reverse transcription and PCR. The company said the tool can enable researchers to obtain the representation of full-length transcripts for experiments with cDNA libraries, RACE-ready cDNAs, or microarray cDNA probes.

PrecisionMed has launched a new PrecisionMed Sample Bank collection in late-onset Alzheimer’s disease for genetics, proteomics, and molecular diagnostics research. The product comprises data that includes the following rating scales: Clinical Dementia Rating, Mini Mental Status Exam and the ADAS-cog, and detailed demographic information, PrecisionMed said in a statement. This controlled collection will supplement an existing Alzheimer’s disease sample collection, which includes matched control subjects collected over the past two years and stored in the PrecisionMed sample bank. PrecisionMed’s sample bank is a repository of human blood, DNA, RNA, sera, plasma, and other body fluid linked to anonymous and audited clinical data.

Filed under

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.